

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED
DURING THE NINE MONTHS OF 2025
OF "SOPHARMA" GROUP**

Annex № 4

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021
And Regulation (EU) 596/2014 of the European Parliament and of the Council
of 16 April 2014**

The persons who are liable for damages caused by false, misleading or incomplete data in this information as of 30.09.2025 are:

*Ognian Donev - Executive Director and Chairman of the Board of Directors of Sopharma AD
Vesela Stoeva – Deputy. - Chairman of the Board of Directors of Sopharma AD
Bisera Lazarova – Member of the Board of Directors of Sopharma AD
Alexander Tchaushev – Member of the Board of Directors of Sopharma AD
Ivan Badinski - Member of the Board of Directors of Sopharma AD*

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. There are no significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - No change of auditors.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. "Sopharma" AD established a subsidiary "SofTech Services" EOOD. On February 28, 2025, the newly established company was entered in the Commercial Register with a share capital of BGN 100 thousand.
- "Sopharma Trading" AD established "Sopharmasy Plus" EOOD – a commercial company registered in Bulgaria by the decision of the Registry Agency № 20250716141706 dated 16.07.2025.
- 1.8. The management believes that the military conflict between Russia and Ukraine could have a serious impact on the Company's activities, since the main part of product sales are realized in Ukraine and Russia. In the nine months of 2025, the company reports a 39,9% growth in sales in Russia compared to 2024 and a 3,5% decline in sales in Ukraine compared to the same period in 2024.

The company has investments in two subsidiaries in Ukraine. As of the date of preparation of the financial statements, the assets of these subsidiaries are not physically affected by military action, but it is possible that in the future the value of these investments may need to be reviewed depending on the development of the war and its impact on the activities of the companies.

"Sopharma" AD informs all interested parties that the consolidated financial statements of the Company as at 30 September 2025 have not been verified by a registered auditor.

Information under Art. 12, para. 1, item 2 of REGULATION No. 2 of 09.11.2021 on initial and subsequent disclosure of information during the process of public offering of securities and admission of securities to trading on a regulated market.

Electronic reference to the place on the website of the public company, where the internal information under Art. 7 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and Directive 2003/6/EC of the European Parliament and of the Council and Directives 2003 /124/EC, 2003/125/EC and 2004/72/EC of the Commission (OB, L 173/1 of 12 June 2014) (Regulation (EU) No 596/2014) regarding the circumstances that occurred in the third quarter of 2025, or an electronic reference to the issuer's

chosen news agency or other media through which the company makes public the inside information:

During the period 01.01.2025 - 30.09.2025, "Sopharma" AD discloses information to the Financial Supervision Commission Authority, the Bulgarian Stock Exchange, the Warsaw Stock Exchange and the public, through the information platform x3news (<http://www.x3news.com>), through the company's corporate website in the "Investors" section (<https://www.sopharmagroup.com/bg/investitori/novini-za-investitori>), on the information site investor.bg (<https://www.investor.bg/bulletin>) and on Infostrefa (<https://infostrefa.com/infostrefa/pl/profil/845,SOPHARMA>).